-
Founded in:
1990-02-07 -
Country:
China -
Address:
No. 88, Taiji Road, Jimo District, Qingdao City, Shandong Province -
Tax NO.:
91370200163570278P -
Registered Funds:
98.3043 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| 1,1-DIMETHYLBIGUANIDE HYDROCHLORIDE |
It can reduce liver glucose production, inhibit intestinal absorption of glucose, and increase the uptake and utilization of glucose by peripheral tissues. It can improve insulin sensitivity by increasing peripheral glucose uptake and utilization.
More
It can reduce liver glucose production, inhibit intestinal absorption of glucose, and increase the uptake and utilization of glucose by peripheral tissues. It can improve insulin sensitivity by increasing peripheral glucose uptake and utilization. |
15537-72-1 | 55 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Diltiazem hydrochloride |
This product is a calcium channel blocker, and its action is related to the inhibition of calcium ion influx during myocardial and vascular smooth muscle depolarization. This product can effectively dilate the epicardial and subendocardial coronary arteries, relieve spontaneous angina pectoris or angina pectoris caused by coronary artery spasm induced by ergonovine; by slowing down the heart rate and lowering blood pressure, it reduces myocardial oxygen demand, increases exercise tolerance and relieves exertional angina pectoris. This product can relax vascular smooth muscle, reduce peripheral vascular resistance, and lower blood pressure; the extent of its blood pressure reduction is related to the degree of hypertension, and only slightly reduces blood pressure in people with normal blood pressure. This product has a negative inotropic effect and can slow down the conduction of the sinoatrial node and atrioventricular node.
More
This product is a calcium channel blocker, and its action is related to the inhibition of calcium ion influx during myocardial and vascular smooth muscle depolarization. This product can effectively dilate the epicardial and subendocardial coronary arteries, relieve spontaneous angina pectoris or angina pectoris caused by coronary artery spasm induced by ergonovine; by slowing down the heart rate and lowering blood pressure, it reduces myocardial oxygen demand, increases exercise tolerance and relieves exertional angina pectoris. This product can relax vascular smooth muscle, reduce peripheral vascular resistance, and lower blood pressure; the extent of its blood pressure reduction is related to the degree of hypertension, and only slightly reduces blood pressure in people with normal blood pressure. This product has a negative inotropic effect and can slow down the conduction of the sinoatrial node and atrioventricular node. |
33286-22-5 | 41 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Clarithromycin |
This product is a macrolide antibiotic, which has an inhibitory effect on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Peptostreptococcus, and Propionibacterium acnes. In addition, it also has an inhibitory effect on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.
More
This product is a macrolide antibiotic, which has an inhibitory effect on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Peptostreptococcus, and Propionibacterium acnes. In addition, it also has an inhibitory effect on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect. |
81103-11-9 | 46 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| α-Mannan peptide |
It can inhibit the synthesis of DNA and RNA and glucose metabolism of cell lines such as S-180 sarcoma, Ehrlich ascites carcinoma and human tongue squamous cell carcinoma Tca8113 in vitro; it can inhibit the growth of Ehrlich ascites carcinoma, S-180 sarcoma and HePA liver cancer ascites tumor in vivo (tumor inhibition rate 63%), can increase peripheral leukocytes, enhance the phagocytic function of the reticuloendothelial system, activate macrophages and lymphocytes, induce thymus lymphocytes to produce active substances, improve and enhance the body's immune function and stress capacity. After being injected into the human body, this product has the effect of activating phagocytes, NK cells, and T.B cell subsets; it has the effect of inducing interferon and interleukin. It can cause chromosomes of tumor cells, viruses, etc. to break and cause apoptosis, and can induce a variety of effector cells and cytokines to produce a "cytokine cocktail" effect, killing viruses and pathogens broadly and inducing apoptosis of tumor cells broadly.
More
It can inhibit the synthesis of DNA and RNA and glucose metabolism of cell lines such as S-180 sarcoma, Ehrlich ascites carcinoma and human tongue squamous cell carcinoma Tca8113 in vitro; it can inhibit the growth of Ehrlich ascites carcinoma, S-180 sarcoma and HePA liver cancer ascites tumor in vivo (tumor inhibition rate 63%), can increase peripheral leukocytes, enhance the phagocytic function of the reticuloendothelial system, activate macrophages and lymphocytes, induce thymus lymphocytes to produce active substances, improve and enhance the body's immune function and stress capacity. After being injected into the human body, this product has the effect of activating phagocytes, NK cells, and T.B cell subsets; it has the effect of inducing interferon and interleukin. It can cause chromosomes of tumor cells, viruses, etc. to break and cause apoptosis, and can induce a variety of effector cells and cytokines to produce a "cytokine cocktail" effect, killing viruses and pathogens broadly and inducing apoptosis of tumor cells broadly. |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Clarithromycin |
This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.
More
This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect. |
81103-11-9 | 46 |